Lilly picks Virginia for the first of its four new US manufacturing facilities
The new $5 billion manufacturing site is set to become the company’s first integrated facility for API and drug product manufacturing.
List view / Grid view
News
GSK outlines $30bn, five-year plan for R&D and manufacturing in the US
The company’s investment strategy will also encompass AI, digital technology and supply chain infrastructure.
Novartis builds on Monte Rosa collaboration with $5.7 billion deal
Expanding its collaboration with the US biotech will add novel molecular glue degrader-based medicines to the pharma company’s pipeline.
European generics firm Zentiva sold in $4.8bn private equity deal
Prague-based pharma company is acquired by GTCR from Advent.
Worldwide Clinical Trials appoints new CEO Alistair Macdonald
He takes over at the CRO from Peter Benton and brings experience from GHO Capital, Syneos Health and INC Research.
ICH to implement M14 Guideline for post-marketing safety submissions
The ICH Assembly’s decision supports progress in promoting international standards for safety assessment of medicines.
Pharma’s UK dissatisfaction mounts as Merck & Co axes $1.3bn expansion
Biotech and research investments from Lilly and AstraZeneca also put on hold as pricing row rumbles on.
In-line pharma monitoring system developed for tablet quality inspection
The novel approach could enhance quality testing applications in pharmaceutical manufacturing.
Obesity drug competition fuels Novo Nordisk restructure
The company’s CEO says the shift will help prioritise investment into obesity and diabetes, the company’s leading therapy areas.
FDA approves first-of-a-kind intravesical drug delivery system for bladder cancer
The innovation is set to change how eligible bladder cancer patients in the US are treated who are unresponsive to traditional therapy.
CPHI Frankfurt 2025 prepares to open its doors
The October event at Messe Frankfurt is expected to welcome more than 63,000 pharmaceutical professionals.
Novartis expands in cardiovascular disease with $1.4bn Tourmaline Bio acquisition
Gains access to potential breakthrough atherosclerotic cardiovascular disease biologic therapy pacibekitug.
WHO adds cancer and diabetes drugs to its essential medicines list
As an important policy tool, the new editions by the WHO mark a “significant” step in broadening access to new medicines with proven clinical benefits.
Servier acquires treatment for autism genetic cause Fragile X syndrome
Deal with Kaerus Bioscience for KER-0193 could be worth $450m to the UK-based biotech.
FDA to modernise review process for developers of ultra-rare diseases
The regulator’s new principles aim to ease the pathway to regulatory approval for rare disease drug developers in the US.
